How can eligible patients apply?

Connect Ovar Coffee with Dr. Debra Richardson

Chief of Gynecologic Oncology, University of Oklahoma

Summary

This episode of Connect Ovar Coffee explores the rapidly evolving landscape of early-phase clinical trials and their role in shaping the future of ovarian cancer treatment. Dr. Debra Richardson explains how modern Phase I trials have evolved beyond simply determining safety to identifying the optimal balance between efficacy and tolerability, giving patients access to promising therapies years before they become widely available.

The conversation highlights the growing importance of:

Precision medicine
Comprehensive biomarker testing including BRCA, HRD, folate receptor alpha, HER2, mismatch repair status, and emerging molecular targets
Antibody-drug conjugates (ADCs) and how they are transforming ovarian cancer care, while noting that research is still underway to determine the best sequencing strategies as more therapies become available.
Emerging innovations including bispecific antibodies, circulating tumor DNA (ctDNA), and artificial intelligence, which may improve patient selection, predict treatment response, and reduce unnecessary toxicity.

Dr. Richardson discusses the importance of considering clinical trials earlier in a patient’s journey whenever appropriate, as they are the driving force behind progress and often provide access to tomorrow’s treatments today.

The discussion concludes with prevention and early detection, including opportunistic salpingectomy, hereditary cancer risk assessment, and ongoing screening research. Dr. Richardson leaves viewers with an optimistic outlook that the pace of scientific discovery, recent FDA approvals, and an expanding pipeline of innovative therapies are bringing the field closer to making ovarian cancer a manageable chronic disease while continuing the pursuit of a cure.

Message of Hope

“We’re in really exciting times right now. We’re seeing more FDA approvals, more treatment options for our patients, and you’re going to see even more approvals in the coming years. Before we find a cure, my goal is for ovarian cancer to become a chronic disease, one where patients can enjoy a full quality of life while continuing to receive effective treatment. We are slowly but surely getting there.”
– Dr. Debra Richardson

Biomarkers and Innovation in Ovarian Cancer

Connect Ovar Coffee with Dr. Angeles Secord

Overview

In this episode of Connect Ovar Coffee, Dr. Angeles Secord, Director of Gynecologic Oncology Clinical Trials at Duke Cancer Institute, discusses how biomarkers, precision medicine, targeted therapies, and clinical trials are reshaping ovarian cancer care.

Key Highlights

Biomarkers are transforming treatment decisions by helping predict prognosis and match patients to the most effective therapies. She emphasizes early testing for BRCA, HRD, Folate Receptor Alpha (FRα), HER2, PD-L1, and other emerging biomarkers.
Precision medicine is becoming increasingly personalized, with different ovarian cancer subtypes requiring distinct biomarker-driven treatment strategies.
Antibody–Drug Conjugates (ADCs) continue to expand rapidly, targeting biomarkers including FRα, HER2, Claudin 6, Cadherin 6, NaPi2b, and B7-H4.
Dr. Secord discusses the global ReNeuS clinical trial for platinum-resistant ovarian cancer, highlighting its goals, patient eligibility, and the importance of clinical trial participation.
Careful management of side effects—including blood count monitoring, infection prevention, growth factor support, and proactive symptom management—is essential to safely deliver newer targeted therapies.
Major updates from SGO and ASCO include promising immunotherapy combinations, new ADCs, first-in-class therapies, and studies moving effective treatments into earlier lines of care.
Early detection remains a major research priority, with promising work underway in circulating tumor DNA (ctDNA), vaginal fluid biomarkers, expanded genetic testing, and opportunistic salpingectomy.

Closing Message

“Every time I go to clinic, my cup gets lifted up again because I see patients that are long-term survivors… That helps me know that we are Ovarcoming every day in this fight against this disease.” – Dr. Angeles Secord

Key Takeaway

The future of ovarian cancer care is increasingly driven by precision medicine. Through comprehensive biomarker testing, innovative targeted therapies, clinical trials, and personalized treatment strategies, meaningful progress continues to improve outcomes and offer renewed hope for patients and families.

Connect Ovar Coffee: Dr. Alexander Olawaiye

This episode features Dr. Alexander Olawaiye, discussing major advances in ovarian cancer treatment, including the ROSELLA clinical trial.

Key Highlights:

1. Ovarian Cancer Challenges:

No reliable early screening methods
Majority diagnosed at advanced stages (Stage III/IV)
Early detection remains a critical unmet need

2. ROSELLA Trial Breakthrough:

Focus on platinum-resistant ovarian cancer
Combines relacorilant (a glucocorticoid receptor antagonist) with nab-paclitaxel
Demonstrated improved progression-free survival and overall survival
No biomarker requirement, making it accessible to more patients

3. Mechanism of Action:

Relacorilant blocks cortisol signaling that promotes chemotherapy resistance
Enhances effectiveness of chemotherapy

4. Safety & Tolerability:

No new major toxicities identified
Side effects consistent with standard chemotherapy

5. Clinical Trial Importance:

Patients in trials often experience better outcomes
Participation helps advance future treatments

6. Health Equity & Access:

Disparities exist in access to care and clinical trials
Need to improve awareness, access, and inclusion

7. Future Outlook:

Rapid growth in new treatments over past decade
Emerging therapies include antibody-drug conjugates
Continued innovation offers hope for patients

Closing Message:

Stay informed, consider clinical trials, and remain hopeful as new treatments continue to emerge.

Innovative Advances in Ovarian Cancer Care

Highlights with Dr. Robert Wenham (Moffitt Cancer Center)

1) The future of gynecologic oncology: access + precision

Major cancer centers can offer earlier access to high-impact clinical trials often where new therapies first show survival benefit.
Operational precision matters: getting the right biomarker and genetic testing, expert coordination, and correct sequencing of therapies.

2) Antibody–Drug Conjugates (ADCs): targeted chemotherapy, evolving fast

ADCs link a potent chemotherapy payload to an antibody that targets cancer-associated markers (e.g., folate receptor alpha).
Wenham frames ADCs as an important evolution: improved targeting and tolerability, with benefits that may be incremental rather than universally “better than chemo.”
Key directions: moving ADCs earlier in treatment, broadening eligibility (less dependence on very high target expression), and combining with other therapies (including immunotherapy).
Example discussed: mirvetuximab as proof of principle; attention to trial design and choosing the right patient niche.

3) Immunity & immunotherapy: making ovarian tumors ‘hot’

Ovarian cancers vary biologically, responses to immunotherapy differ by subtype (e.g., high-grade serous vs. endometrioid/clear cell).
Core challenges: immune-suppressive tumor microenvironment and limited immune infiltration; early checkpoint inhibitor response rates were low in ovarian cancer.
Promising strategy: thoughtful combinations that change the immune environment (e.g., chemo scheduling, anti-VEGF, PARP-related antigen load).
Highlighted trial concept: adding pembrolizumab (Keytruda) to weekly paclitaxel (± bevacizumab) for platinum-resistant disease showed encouraging outcomes and is being evaluated by regulators.

4) Minimum Residual Disease (MRD): a window for earlier immune benefit

MRD (microscopic disease after surgery/therapy) may represent a ‘window of opportunity’ where immunotherapy could work better than in bulky disease.
Approaches discussed: second-look assessment (research context only) and circulating tumor DNA (ctDNA) for detecting residual disease.
Important caution: MRD strategies are investigational – patients should not pursue second-look surgery outside a trial setting.

5) Surgical innovation: fluorescence-guided detection

A fluorescent dye approach (antibody + near-infrared signal) can help surgeons identify lesions not seen by standard techniques.
In trials, clinically significant additional lesions were detected in a meaningful subset of patients, potentially improving completeness of cytoreduction.
Adoption barriers: technology/camera compatibility and real-world reimbursement logistics.

6) Vaccines: not prime time yet, but momentum is building

Goal: train the adaptive immune system to recognize tumor antigens.
Three strategies discussed: shared-antigen vaccines, personalized neoantigen vaccines, and dendritic cell/whole-lysate vaccines.
Current reality: generally tolerable with limited efficacy so far; optimism remains for future breakthroughs.

7) CAR‑T and cellular therapy: early promise, complex delivery

CAR‑T involves engineering a patient’s immune cells to target cancer-specific receptors; persistence and exhaustion remain key hurdles.
Wenham described a CAR‑T trial targeting follicle-stimulating hormone receptor (FSHR), aiming for selectivity to ovarian cancer cells.
Current status shared: tolerability appears favorable so far; efficacy signals are preliminary; patient selection and timing matter.

Key takeaways: Ovarcoming the old narrative

Consider specialty care early: a gynecologic oncology expert can ensure top-level standard-of-care testing and sequencing.
Ask about biomarker/genetic testing and whether a clinical trial is appropriate at your stage and line of therapy.
Innovation is accelerating. Progress may not be ‘overnight,’ but survival and treatment options continue to improve.

“Let’s Ovarcome our historical perspective and realize that things are much better now and are only going to get better in the near future.”

Featuring Dr. Pedro Ramirez, MD

Chair, Department of OB-GYN | Houston Methodist Neal Cancer Center

In this episode of Connect Over Coffee, Dr. Pedro Ramirez, one of the world’s leading gynecologic oncologic surgeons, shares evidence-based insights on ovarian cancer surgery, evolving treatment strategies, and how patients can be empowered to make informed, collaborative decisions about their care.

Patient-Centered Surgical Decision-Making
Dr. Ramirez emphasizes a critical principle:
“A good surgeon knows how to operate. A great surgeon knows when not to operate.”

Surgery First vs. Chemotherapy First
Five major randomized clinical trials—including the landmark TRUST trial—demonstrate no difference in overall survival between:

Primary debulking surgery followed by chemotherapy, and
Neoadjuvant chemotherapy followed by interval surgery

However, chemotherapy first is consistently associated with fewer complications and safer outcomes. As a result, 80–85% of patients today receive chemotherapy first, a major shift from earlier practice.

Patients should ask:

What is the likelihood all visible disease can be removed?
What evidence supports this treatment sequence?

Surgical Advances & De-escalation
The field is moving toward less aggressive, more precise surgery, including:

Increased use of minimally invasive surgery during interval debulking
Investigation of fluorescence-guided surgery to detect residual disease (still experimental)
Growing exploration of whether some patients may not need surgery at all if modern therapies fully control disease

Recovery & Quality of Life
Enhanced Recovery After Surgery (ERAS) protocols are now standard at leading centers. These include:

Early eating and walking
Limited IV fluids and opioids
Aggressive blood clot prevention

ERAS reduces recovery time from weeks to days, improving quality of life without compromising safety

HIPEC: Use With Caution
Heated Intraperitoneal Chemotherapy (HIPEC) is not standard of care in the U.S. It may benefit a narrow group of patients undergoing interval surgery but carries higher complication risks and should only be considered at highly experienced centers

Fertility Preservation
For young patients:

Advanced ovarian cancer typically precludes fertility preservation
Early-stage or non-epithelial tumors may allow preservation of the uterus and one ovary
Pregnancy is generally advised 1–2 years after treatment, once recurrence risk is better understood

Looking Ahead: 2026 and Beyond
Dr. Ramirez is optimistic about the future of ovarian cancer care that will likely witness:

Molecular profiling as standard of care
Antibody-drug conjugates and targeted therapies
Higher response rates (30–40%) and durable disease control
Expansion of clinical trials (30+ trials anticipated at Houston Methodist in 2026)

Ovarian cancer is increasingly being managed as a chronic disease, allowing patients to live fuller lives while on treatment.

Dr. Ramirez’s final Message to Ovarcomers
Be informed. Ask questions. Seek second opinions when needed. Choose care teams that treat you, not just the disease. Above all, there is real hope, driven by science, collaboration, and patient empowerment.

Dr. Premal Thaker

Transforming Treatment in Ovarian Cancer: Breakthroughs offering Hope

Guest: Dr. Premal Thaker

Director of Gynecologic Oncology at Washington University School of Medicine in St. Louis

Antibody-Drug Conjugates (ADCs)

ADCs are revolutionizing treatment: There has been an “explosion” in the use of antibody-drug conjugates across gynecologic cancers.
Examples include:
- HER2-positive targeting ADCs showing promise across ovarian, cervical, and endometrial cancers.
- New ADCs for folate receptor alpha and NaPi2B pathways are emerging with improved tolerability.

Glucocorticoid Antagonists

Relacorilant, a glucocorticoid receptor antagonist, demonstrated benefit in platinum-resistant ovarian cancer, presenting a non-chemotherapy mechanism of action.

Breakthrough Clinical Trials

Keynote B96 Trial

First immunotherapy trial with positive results for platinum-resistant ovarian cancer.
Combined weekly paclitaxel + bevacizumab ± pembrolizumab.
Results:
- Progression-Free Survival (PFS): +1.9 months
- Overall Survival (OS): +4.2 months
Notable because previous immunotherapy trials failed to meet statistical significance.

Ovation 3 Trial (under Dr. Thaker’s leadership)

Investigating intraperitoneal IL-12 (an interleukin) with chemotherapy for newly diagnosed patients receiving neoadjuvant therapy.
Early results show:
- Overall Survival benefit: +13 months
- PFS benefit: +3 months
This trial aims to reshape the tumor microenvironment and is actively recruiting patients.

Combination & Maintenance Therapies

Personalized Treatment by Biomarker

PARP inhibitors + bevacizumab are effective for HRD-positive patients.
Ongoing efforts to:
- Extend maintenance therapy options for HR-proficient patients.
- Explore novel maintenance agents and sequencing strategies.

Future of ADCs

More inclusive ADCs that don’t require strict biomarker expression (e.g. folate receptor alpha levels).
Drugs like RDXD show >50% response rate with favorable side effects.
Challenge: Figuring out sequencing of similar ADCs to maintain efficacy.

Biomarkers & Testing

Importance of NGS (Next Generation Sequencing)

Strong advocacy for NGS panel testing for all patients.
Enables:
- Detection of actionable mutations (e.g., CCNE1 amplifications, folate receptor alpha expression).
- Eligibility for clinical trials or targeted therapy.

Emerging Biomarkers

Claudin 6, cadherin, and p53 among others are under investigation.
Some may offer high prevalence (60–80%) in ovarian cancer, enhancing therapy reach.

Disparities & Global Challenges

Many global regions lack access to NGS testing, limiting treatment personalization.
Even in the U.S., disparities exist in non-academic or rural settings.
Dr. Thaker emphasizes educating both patients and providers to overcome systemic gaps.

Key Concepts Explained<

Progression-Free Survival (PFS): Time until disease worsens.
Overall Survival (OS): Time until death from any cause.
Both are essential clinical trial endpoints with regulatory importance.

Other Scientific Highlights

Low-grade ovarian cancer: Now has its own FDA-approved treatment (vemurafenib + defactinib).
Endometrial cancer is now more common than ovarian cancer and rising due to obesity.
GLP-1 medications may help lower cancer risk (still under research).

Research & Clinical Trials: The Future

Clinical trials are now better supported with patient-friendly measures (e.g. travel support).
Patients who don’t initially respond can quickly return to standard of care.
The future includes:
- More non-ADC therapies (e.g., tyrosine kinase inhibitors, CDK2 inhibitors).
- Greater personalization of treatment by tumor subtype and biomarker profile.

Dr. Thaker’s Key Message: Hope Through Innovation & Access

“Ovarian cancer care is entering a transformative era—where science is smarter, treatments are more targeted, and every woman deserves access to that hope.”

Dr. Thaker emphasizes that we are witnessing major progress in ovarian cancer treatment, with innovations like antibody-drug conjugates, biomarker-driven therapies, and clinical trials that are finally showing survival benefits.

But she’s also clear: these advances must reach everyone.

That means:

Expanding genetic testing (NGS) to guide personalized care
Ensuring equity in clinical trial access
And educating both patients and providers so no one is left behind

Dr. Emil Lou

Topic: Breaking the Code: Disrupting Cellular Communication in Ovarcoming Ovarian Cancer

Guest: Dr. Emil Lou

Medical Oncologist, University of Minnesota Medical School

Key Highlights:

Understanding Ovarian Cancer Challenges

Ovarian cancer symptoms often go undetected or are misunderstood, leading to late-stage diagnosis.

Dr. Lou emphasizes the need for better education in medical training and encourages mainstreaming ovarian cancer in curricula.

A core message is that we must listen to the voice of the patients. Many patients feel dismissed when reporting symptoms. This needs to change.

Research & Innovation

1. Personalized Medicine & Genomics

Focus: Using genomic testing to understand mutations (e.g. BRCA1/2, HRD status) that guide treatment decisions.
Goal: Deliver precision therapy, matching patients with treatments based on genetic tumor profiles.
Example: PARP inhibitors are used for patients with BRCA mutations, showing how genetics can inform targeted care.

2. Immunotherapy and Tumor Microenvironment

Insight: Unlike other cancers, ovarian tumors often have a “cold” immune microenvironment, meaning they don’t elicit strong immune responses.
Scientific Priority: Researchers are working to “heat up” the tumor environment to make immunotherapies more effective.
Future Direction: Combining immune-based therapies with other treatments to make the cancer more visible to the immune system.

Clinical Trials & Underrepresentation

Need for More Inclusive Research

Lou stresses the urgency of increasing access to clinical trials, especially for underserved communities.
There’s a need for:
- Greater participation diversity
- Earlier intervention trials
- Better funding support for rare cancers like ovarian cancer

Biological Complexity of Ovarian Cancer

Heterogeneity of the Disease

Fact: Ovarian cancer is not one disease—it includes multiple subtypes (e.g., high-grade serous, endometrioid, mucinous).
Challenge: Different subtypes respond differently to treatments.
Scientific Need: Tailored research for each subtype, rather than lumping all under a generic treatment model.

Barriers in Science and Medicine

Lack of Education in Medical Training

Lou criticizes how little time ovarian cancer gets in traditional medical school curricula.
This knowledge gap contributes to missed diagnoses and inadequate patient education.
He advocates for mainstreaming ovarian cancer education in both public health and professional settings.

Emotional Insights

Dr. Lou shares deeply emotional reflections on the psychological and spiritual resilience he sees in his patients. He draws strength from their courage and celebrates organizations like Ovarcome for creating empowering spaces.

Final Message from Dr. Lou

– To patients: You are seen, heard, and valued. Never doubt your voice.
– To doctors & researchers: Let empathy and listening guide your science.
– To the public: Support ovarian cancer education and advocacy. It can save lives.
“Ovarian cancer is not just a disease. It’s a deeply human experience that deserves more attention, research, and heart.”

Dr. Brian Slomovitz

Topic: Latest Advances in Gynecologic Cancers
Guest: Dr. Brian Slomovitz,
Director of Gynecologic Oncology, Mount Sinai Medical Center of Florida

Key Highlights:

1. Genetic & Molecular Overlap Between Ovarian and Endometrial Cancers

Shared genetic risks involve BRCA mutations and Lynch syndrome.
Synchronous cancers are possible and require careful molecular and histological analysis to distinguish from metastasis.
Clinical trials require precise tissue origin identification.

2. Endometriosis and Ovarian Cancer Risk

Endometriosis increases ovarian cancer risk 2–4x, especially for clear cell and endometrioid types.
Surgical ablation, hormone therapy, and conservative management are effective.
Aggressive removal must be balanced with safety (e.g., bladder or bowel involvement).

3. Biomarkers and Testing

CA-125 remains the primary biomarker, despite limitations.
Signatera is under study for early detection of recurrence via blood tests.
Tumor profiling (HER2, KRAS, alpha folate receptor) supports personalized treatment planning and recommndations.

4. HRD Testing and PARP Inhibitors

HRD and BRCA+ patients respond best to PARP inhibitors.
HRP patients show no proven overall survival benefit—FDA re-evaluation ongoing.
HRD testing is essential for personalized treatment planning.

5. ROSELLA Trial – for Platinum-Resistant Ovarian Cancer

Relacorilant (non-chemo) showed a 30% lower recurrence risk and 31% lower death risk.
FDA approval pending – trial completed.
Well tolerated and may expand treatment options.

6. Global Access Challenges

US access faster than global rollout.
Patients should explore global clinical trials for earlier access.
Sponsors are urged to accelerate global availability.

7. Immunotherapy: Ovarian vs. Endometrial Cancer

Endometrial cancer responds well to immunotherapy—even for microsatellite-stable cases.
Ovarian cancer is less responsive due to being a ‘cold tumor’ with low immune visibility.

8. Metabolism, Inflammation, and Cancer

Obesity, diabetes, and inflammation raise cancer risk.
Metformin had mixed results; GLP-1 drugs (Ozempic etc.) are promising for prevention and risk reduction.
Metabolic health management may aid treatment and prevention.

9. Low-Grade Serous Ovarian Cancer

Distinct disease from high-grade – hormone-sensitive, chemo-resistant.
FDA approval for MEK inhibitors and CDK4/6 inhibitors shows promise.
Specialist consultation is critical for accurate diagnosis and treatment.

10. Endometrial Cancer: A Growing Crisis

Now deadliest gynecologic cancer, surpassing ovarian.
Advances include ADCs (e.g., Trastuzumab Deruxtecan), hormonal agents, and PARP inhibitors.
More trials are underway to identify patient-specific responses.

Final Messages from Dr. Slomovitz

Seek second opinions and the best possible care early. The timing of enrolment in Clinical Trials matters. Do not delay in seeking options available to you.

Hope is growing. Keep Ovarcoming!

Dr. Lorenzo Cohen & Alison Jefferies

Topic: MIF of SIX in Ovarcoming Ovarian Cancer
Guest: Dr. Lorenzo Cohen, Director of Integrative Medicine at MD Anderson Cancer Center & Alison Jefferies, Board-Certified Wellness Coach, Educator, and Author

The Mix of Six: A Holistic Lifestyle Prescription

Love & Support

Foundation for all behavior change. Enhances biological resilience and reduces stress. Guests encouraged to seek support from Ovarcome, hospitals, online networks, and non-family members.

Stress Management

Chronic stress fuels cancer progression. Tools include yoga, CBT, meditation, tai chi, breathwork. Daily and consistent practice is essential.

Sleep

Adequate sleep improves immune function, metabolism, and cognition. Guests emphasize sleep routines, reducing light exposure, and managing caffeine/alcohol intake.

Exercise

Reduces treatment side effects, enhances mood, boosts immunity. Cardio, resistance training, stretching, and reduced sedentary behavior are key.

Nutrition

Guests highlight a plant-centered Mediterranean diet, combining animal protein in moderation and plant protein in abundance. Focus is on fiber and gut health, reduced processed foods and over-reliance on probiotics.

Environment

Limit exposure to toxins and digital overstimulation. Use tools like EWG.org to identify safe personal and household products.

Real-Life Applications & Recommendations

Sample Daily Routine

Wake after 7+ hours of sleep
Start with water or green tea
Morning or evening exercise (walk, yoga, etc.)
Eat plant-rich meals (beans, greens, whole grains)
Use a standing desk and walk after meals
Practice daily mindfulness (morning/evening)
Monitor hydration via urine color (light yellow = optimal)

Gut Health Spotlight

Avoid excessive probiotic supplements – please speak with your physician
Emphasize plant-based fiber (30–50g/day)
Reduce sugar intake and processed foods
Stay hydrated and especially monitor water intake while increasing fiber

Takeaway Messages

You’re already doing a lot – focus on progress over perfection
Anchor changes in core values and create meaningful goals
The Mix of Six will help you enhance quality of life and long-term health
You may not control your diagnosis, but you can influence your journey forward

Dr. Tyler Hillman

Topic: Granulosa Cell Tumors, What You Should Know
Guest: Dr. Tyler Hillman, Associate Professor, University of California, San Diego

Key Highlights: Research & Clinical Insights

GCT as a Rare Cancer: Affects ~0.5 to 1 in 100,000 women. Characterized by hormone (estrogen) overproduction.
Research Innovation: Dr. Hillman’s lab creates tumoroid and organoid models for drug testing. Key discovery: Glucocorticoids promote GCT growth; blocking these hormones may be a treatment strategy.
Repurposing Drugs: Exploring drugs from breast cancer and hormonal disorders (e.g., aromatase inhibitors, Lupron, ketoconazole).

Treatment & Clinical Management

Limited Chemotherapy Efficacy: ~40% response rate. Carefully balanced use to maintain quality of life.
Surgery as a Mainstay: Often repeated (3–4 times per patient). Recommended minimum 1-year interval between surgeries.
Hormonal Therapy Post-Surgery: Use of aromatase inhibitors and Lupron. Side effects include estrogen deprivation symptoms and bone density loss.

Juvenile vs. Adult GCT

Classification based on pathology, not age. Adults can have juvenile GCT and vice versa. Juvenile type is ~5% of all GCTs.

Clinical Trials & Access

No open GCT-specific trials currently. Endocrine and immunotherapy trials are promising. Emphasis on collaborative care models with remote expert consultations.

Challenges in Rare Cancer Research

Funding gaps, especially for surgical and non-patented drug studies. Industry funding supports drug development but overlooks survivorship studies.

Patient Empowerment & Advocacy

Ask care teams: “How many GCT cases have you treated this year?”
Seek specialists who regularly treat rare cancers.
Community support via groups like Facebook and Overcome.org is crucial.

Role of AI

Currently supports research and literature review. Future potential in AI-driven treatment plans and predictive diagnostics.

Final Messages

Advocate for yourself—especially younger women.
Stay connected through community networks.

“Be involved. Stay connected. You are not alone.”

Dr. Elizabeth Swisher

Topic: Innovations in Ovarian and Gynecologic Cancers
Guest: Dr. Elizabeth Swisher, Professor & Director of Gynecologic Oncology, Fred Hutch

Key Highlights of our episode

We talked about: Precision Oncology & Progress

Personalized Treatment: Shifting from “one-size-fits-all” to personalized approaches based on molecular tumor profiling.
Functional Precision Medicine: Using biopsies and AI to identify cancer vulnerabilities and tailor treatments early in the disease.
Antibody-Drug Conjugates (ADCs): A major advancement delivering targeted chemotherapy directly to cancer cells, reducing toxicity.

We discussed: Clinical Trials & Therapy Advances

PARP Inhibitors: Effective for BRCA-mutated and HRD+ cancers, mostly used in maintenance settings due to toxicity when combined with other therapies.
ADC + PARP Combo: Being explored but limited by cumulative toxicity.
Clear Cell & Endometrioid Ovarian Cancers: More hormonally driven, with parallels to endometrial/breast cancers—CDK inhibitors show promise here.
Rare Subtypes (e.g., Granulosa Cell Tumors): New trials are opening, providing hope after years of limited progress.

Recruiting: CHANCES Study (Clonal Hematopoiesis in Cancer Survivors)

Investigating blood-based predictors of secondary cancers (especially leukemia/MDS) due to platinum and PARP exposure.
Eligibility: Ovarian cancer survivors with past platinum and/or PARP exposure. Blood draws every 6 months. Nationwide enrollment.
Goal: Predict and eventually prevent therapy-related secondary blood cancers.

Role of Genetic Testing for Prevention

Up to 20% of ovarian cancers are hereditary. Earlier and broader testing (even pre-diagnosis) can prevent cancers through proactive interventions.
Emphasis on shifting genetic screening into primary care and mainstream medicine.

Recommendations for Ovarcomers

Participate in Clinical Trials
- Consider and look up details of the CHANCES Study if you had platinum/PARP exposure or persistent blood count issues.
- Use Ovarcome’s clinical trial portal or contact Dr. Swisher’s team directly.
Get Genetic Testing Early
- Even if you don’t have cancer, knowing your hereditary risk can inform preventive strategies.
- Encourage family members to get tested, especially if there’s a family history.
Push for Second Opinions
- If your treatment plan doesn’t feel right, seek another expert view
Stay Informed on New Therapies
- Keep up with developments in ADCs, immunotherapy, and molecular profiling—they are redefining gynecologic cancer treatment.
Advocate for Inclusivity in Trials
- Raise awareness about the exclusion of highly resistant cases from trials—those patients need options most.

Dr. Renee Stubbins

Topic: Oncology Nutrition, Lifestyle Wellness, and Cancer Recovery
Guest: Dr. Renee Stubbins, Oncology Dietitian, Houston Methodist

Anti-Cancer Diet & Food Choices

Focus on a balanced, plant-based diet (not necessarily vegetarian).
Whole foods > food products; avoid ultra-processed, shelf-stable items.
Rule of thumb: if you can understand the ingredients, it’s likely safe in moderation.
Water intake is crucial; cold plunges and saunas help indirectly via stress reduction.

Protein, Meat, & Plant Alternatives

Limit red meat to 12–18 oz/week; choose grass-fed AND grass-finished options.
Plant-based proteins to include: soy, beans + rice, quinoa, flax, chia, nuts.
Watch labeling and sourcing — local farms may use organic practices even if not certified.

Supplements & Safety

Vitamin D + Calcium recommended, especially for women 40+.
Avoid high-dose Vitamin C during chemotherapy (especially platinum-based regimens).
Omega-3 is good post-treatment. Avoid herbal supplements unless physician-approved.
Many supplements lack regulation — be cautious and consult healthcare providers.

Hydration & Electrolytes

Drink ~64-72 oz/day; needs increase during treatment or in heat.
Use urine color to monitor hydration; balance electrolytes with coconut water or low-sugar powder blends.
Don’t overhydrate: can dilute sodium/potassium levels.

Cooking Oils & Smoke Points

Olive oil: great for finishing dishes (low smoke point).
Avocado oil: ideal for roasting/sautéing (high smoke point).
Canola, butter, lard better for high-heat applications — but less healthy.

Lifestyle, Sleep & Exercise

Sleep is recovery time — aim for 8 hrs; nap if tired during treatment.
Light morning or evening walks are excellent — motion maintains energy and muscle tone.
Sunlight improves mood and vitamin D, but wear sunscreen and go out during low UV hours.

Final Message from Dr. Stubbins

“Eat your fruits and vegetables, stay active, and get lots of rest and sunlight.”

Dr. Erin Stevens

Topic: Compassionate Cancer Care, Survivorship, and Innovations in Treatment
Guest: Dr. Erin Stevens, Surgical Oncologist, Prevea Health

Key Highlights of Our Episode

Language & Emotional Support

Dr. Stevens challenges the use of “war” metaphors in cancer, emphasizing they can invalidate feelings like fear, grief, or acceptance.
Normalizing the emotional spectrum—including survivor’s guilt and post-treatment anxiety—is key to whole-person care.
Providers are encouraged to create safe spaces where patients can “sit in the hard” moments without pressure to stay positive.

Rural Cancer Care Challenges

Rural patients face limited access to clinical trials, diagnostic tests, and support services.
Priorities like farm seasons, snow conditions, and long travel must be honored and worked around, while optimizing care
Despite resource gaps, community support systems (neighbors, churches, meal trains) are strong in rural settings

Clinical Trials & Accessibility

Trials requiring travel are often deemed burdensome, further reducing participation—bring drugs to patients when possible.
Better consent education and simplified language improve understanding and engagement.
Low-barrier trials (e.g., blood sample studies) are popular and impactful.

Long-Term Side Effects

Neuropathy and chemobrain are common, persistent side effects.
Speech language pathologists are underused allies in managing cognitive symptoms.
Sleep issues, surgical menopause, and emotional fatigue require honest counseling and daily lifestyle strategies (like journaling, temperature control, or digital detox).

Rare Tumors & Personalized Care

Dr. Stevens highlights carcinosarcomas and endometrial stromal sarcomas—rare and aggressive tumors.
New clinical trials are targeting HER2 mutations in gynecologic cancers.
Personalized care means understanding and honoring patient goals, not just prescribing standard therapies.

Recommendations for Ovarcomers

Feel everything. You don’t have to be positive all the time—your full range of emotions is valid.
Use simple tools like brain games, gratitude journaling, sleep hygiene, and nature walks—daily.
Ask about eligibility for clinical trials, even low-effort ones (e.g., blood-based biomarker studies).
Learn your mutation profile. Ask if your cancer has HER2, BRCA, HRD, or other actionable markers.
Celebrate wins. Even small, good news moments deserve recognition—you are living life and Ovarcoming strong.

Katherine Lawrence

Key Highlights

Katherine Lawrence, a certified nutritionist, reversed stage 4 endometriosis and reproductive issues through a whole food, plant-based diet.
This episode emphasizes how food choices directly impact mental health, sleep quality, and long-term energy.
Dairy intake (especially for ovarian cancer survivors), ultra-processed food, and high-fat meat consumption are best avoided or used in minimal moderation, while embracing whole, plant-based alternatives.
Fiber-rich Mediterranean-style diet minus excess oil and animal products is recommended by Katherine.
Diet and lifestyle shifts may support cancer recovery, prevention, and resilience.

Actionable Takeaways

Start by ‘crowding out’ processed foods—gradually introduce more veggies, legumes, and greens.
Embrace soy in moderation (tofu, tempeh, miso) as a protective element.
Replace dairy with fortified plant milks to reduce cancer-linked IGF-1 growth factors.
Prioritize cruciferous vegetables—powerful allies against cancer progression.
Include red miso, kimchi, and kombucha to nourish gut flora and support immunity and
Nourish the whole self: prioritize movement, rest, mindfulness, and emotional nourishment alongside diet.

Dr. Kara Long

Topic: Surgical Advances, Prevention, and Personalized Care in Gynecologic Cancers

Guest: Dr. Kara Long, Surgeon & Oncologist, Memorial Sloan Kettering Cancer Center

Key Highlights of our episode

Surgical Innovations

Surgery types include diagnostic, debulking, and preventive approaches.
Open surgery remains gold standard for extensive disease; robotic/minimally invasive surgery considered in selective cases.
Second-look surgery is being re-evaluated in the era of maintenance therapies.

Clinical Trials & Second Look

Second-look trials (e.g. with Bevacizumab) assess minimal residual disease and inform next treatments.
Used for research and tailoring therapy, especially in remission or recurrence context.

AI, Genetics, & Early Detection

AI may assist in surgical planning and risk stratification.
Genetic knowledge essential—universal genetic awareness is necessary.
Nanotechnology with carbon nanotubes + AI is being explored for early cancer fingerprint detection.

Prevention Strategies

Fallopian tube removal emerging as risk-reducing option.
Clinical trials (TUBA-WISP, SOROC, Protector) explore delaying ovary removal in high-risk women.
Even average-risk women benefit from opportunistic salpingectomy during unrelated surgeries.

Personalized Considerations

Surgery must improve quality or quantity of life—sometimes avoided based on fitness, age, or minimal benefit.
Age and subtype matter: personalized medicine is advancing using molecular profiling.
Importance of respecting patient goals and values in decision-making is emphasized

Recommendations for Ovarcomers

Ask your care team about second-look surgery or relevant clinical trials.
Consider fallopian tube removal during hysterectomy or sterilization procedures.
Know your genetic status—especially BRCA and other high-risk markers.
Inquire about opportunities for minimally invasive surgery when appropriate.
Build a survivorship plan with your surgeon that aligns with your life goals and values.

Dr. Marta Crispens

Topic: Ovarian Cancer Recurrence, Innovation, and Patient Support
Guest: Dr. Marta Crispens, Director of Gyn Oncology, Vanderbilt Ingram Cancer Center

Understanding Recurrence & Drug Resistance

Ovarian Cancer is Heterogeneous: High-grade serous carcinoma differs from low-grade; requires personalized treatment.

Recurrence Causes:

Small resistant cells survive initial treatment.
50% of patients lack DNA damage repair defects → poorer outcomes.

Drug Resistance Factors:

Molecular changes, drug transport issues, tumor microenvironment.

Treatment & Trials

Immunotherapy Challenges:

PD-1 inhibitors haven’t been as successful in ovarian cancer.

Emerging Solutions:

IL-4 & macrophage modulation to unlock immune response.
Cryptic antigens: exposing hidden cancer targets to T-cells.
CAR-T cell therapy: experimental, promising but early-phase.

Targeted Therapies:

Antibody-drug conjugates (ADCs) like Elahere.
Exploring less toxic payloads and more specific cancer markers.

Personalized Protocols

Desensitization for Drug Allergies:

Protocols help allergic patients tolerate key chemo drugs.
Example: tiny-dose infusions (in hours, not days) with antihistamines.

PARP Inhibitors:

Standard use: 2 years.
Few patients may benefit from longer usage—but risks like leukemia warrant caution.

Patient-Centered Guidance

Side Effect Management:

Be honest with providers.
Use palliative care for symptom management.
Consider evidence-based integrative approaches: yoga, acupuncture.

Emotional Navigation:

First appointments are overwhelming—processing takes time.
Balance treating cancer and caring for the person, as the provider team.

Call to Action

Support Clinical Trials:

Join trials at every stage: diagnosis, recurrence, maintenance.

Advocacy:

Federal research support reductions threaten progress.
Urge lawmakers to fund science.

Final Messages

“More isn’t always better—but balance is.”— Dr. Marta Crispens

Dr. Robert Bast

Topic: CA125, Early Detection, and Innovative Therapies for Ovarian Cancer
Guest: Dr. Robert Bast, Co-Founder of CA125 and Leading World Renowned Oncologist

CA125 and Its Evolution

CA125 is a glycoprotein marker for ovarian cancer, developed by Dr. Bast.
Initially for recurrence monitoring, it’s now used in combination for diagnosis and early detection.
Limitations: Not all cancers express CA125; may rise due to non-cancerous causes.

Advances in Early Detection

NRROS Trial: Annual CA125 + risk algorithm + ultrasound = 30–34% late-stage reduction.
New 4-marker panel shows promising earlier detection (up to 22 months before clinical symptoms).
Monitoring of autoantibodies (e.g., p53) under trial to further refine early detection.

New Therapies & Innovations

SIK2 Inhibition: Increases chemo and immunotherapy sensitivity; Phase 1 trials underway.
Imprinted Genes: Re-expression of genes like DIRAS3 may suppress tumor growth and promote autophagy.
CAR-NK Therapy: Natural killer cells engineered for targeted attack with less toxicity (in trial).

Specialized Research (SPORE)

Sponsored by NCI to fast-track lab-to-clinic cancer research.
Includes improving PARP inhibitors, antivascular agents, NK cell therapies.

Screening and Monitoring

CA125 still standard for recurrence; not yet for population-level screening.
Emphasis on stage shift >20% as potential future benchmark for adoption.

Key Messages from Dr. Bast

“Never give up.” Research is progressing, offering hope through early detection and new treatments. Collaboration and innovation continue to drive the field closer to better outcomes and eventual cures.

In progress. Please send us an email at info@ovarcome.org with your interest for the longer stay home option. We will share the reservation details with you.

Via OvarCare Counseling we are pleased to offer: Up to 6 sessions of support for up to 6 months Meetings by phone in any location in the U.S. Supportive services to OvarCare grant recipients Information, resources, referrals as needed and requested Our OvarCare counseling sessions are designed to provide support through the journey of Ovarcoming Ovarian Cancer and are not deemed to be psychotherapy services. Our members are ready to provide compassionate and meaningful support via active listening, providing gentle guidance in navigating the often-challenging course of diagnosis, treatment and survivorship, and in providing effective tools and resources to Ovarcome. Please complete the fields below to register for our counseling program: We are here to Ovarcome with you. Welcome to our safe and friendly space. This is a complimentary service as part of our OvarCare Program and is currently available in English only.
Information
Name: *
Date of birth: *
Email Address: *
Address: *
Do you consent to receiving text messages from your OvarCare Support Services?: *	YesNo
Share with us the best way to reach you: *	EmailPhoneText MessageAll of the above
Primary Phone Type: *	MobileLandline
Please indicate your time zone: *	Eastern TimeCentral TimeMountain TimePacific Time Hawaii-Aleutian Time
What do you wish to accomplish from these support sessions? Please share your personal goal: *
Please carefully review the acknowledgements below: 1. OvarCare support services are designed to provide emotional and informational support and is not intended to provide any medical guidance. It is also not intended to provide psychotherapy, crisis management critical mental health issues2. You will be offered up to 6 counseling sessions for up to 6 months as part of this program. You will be contacted via the information you provide to us. Ovarcome is not responsible to maintain privacy of information if provided outside of the channels indicated on the form3. You agree to indemnify, defend, release and hold harmless Ovarcome, their employees, officers, directors, agents, successors and assigns, against all liabilities, claims, causes of action, damages, judgments, costs or expenses, including attorney's fees, caused by, resulting from or which arise in connection with your participation in OvarCare Support Services Program
Acknowledgement of My Consent BY CHECKING THIS CONSENT, I CERTIFY THAT: I have carefully read and consent to the terms and conditions stated herein.
Name: *
Date: *

The application process has been designed in partnership with our partner hospitals.

Please apply online for our OvarCare Grant.